Posts tagged:

vaccine materials

a scientist in a clean suit works on a GreenLight bench

Business Insider: COVID-19 vaccines sparks expansion of RNA research

Business Insider reports on GreenLight Bioscience’s plans to expand its RNA research work, including to include human therapeutics. An extract from the article is below:

For instance, GreenLight Biosciences expanded its mRNA work last year from focusing on pesticide alternatives to include human therapeutics. Now, GreenLight is riding the mRNA hype to a public debut, agreeing to a $1.2 billion special-purpose acquisition company deal in August.

“GreenLight aims to solve some of the world’s biggest problems with RNA, from affordable vaccines and therapies to protecting honeybees,” GreenLight CEO Andrey Zarur said in a statement, adding that clinical trials for its COVID-19 vaccine were scheduled to begin next year.

Read the full article here.

Find out more about how GreenLight manufactures RNA here.

By 0 Comments

VP of marketing Catie Lee being interviewed in a Greenlight factory

News10NBC: GreenLight Biosciences opens new RNA facility in Rochester

Local TV station News10NBC reports on the opening of our new RNA production facility in Rochester. An extract is below.

Workers say this plant- has manufactured more RNA than anywhere else on earth and this is a big step for those in manufacturing for human, animal, and plant health.

“GreenLight Biosciences is at the start of something really exciting we’re using RNA to solve some of the world’s biggest problem,” GreenLight Biosciences marketing director Catie Lee said.

Watch the report here.

Find out more about how GreenLight manufactures RNA here.

By 0 Comments

some people in hazmat suits rest after a hard day's work

Unherd: Why third jabs are inevitable

Amin Khan, Head of Vaccines at GreenLight Biosciences, speaks to Unherd a wider piece about why third jabs are inevitable.

This image has an empty alt attribute
Credit: Unherd/Amarjeet Kumar

Amin Khan, Head of Vaccines at GreenLight Biosciences, speaks to Unherd about the ability to rapidly rollout new mRNA vaccines in a wider piece about why third jabs are inevitable. Extracts below:

Amin Khan, head of vaccines at the biotech firm GreenLight, says that you can get a new variant-specific mRNA vaccine ready to go in a few weeks. And if the new version simply targets a slightly modified version of the spike protein, as the existing vaccines do, it won’t need much in the way of testing and regulatory approval. Changing your manufacturing system is more complicated, “but within two or three months, you can get a new variant to the market”.

Playing whack-a-mole with new variants isn’t a long-term solution, though. The hope is that “third-generation” vaccines will be capable of covering all the existing variants and most foreseeable future ones. But, says Khan, that’s a bit more complicated. A more complete version might target other parts of the virus than the spike protein; that would mean a much more rigorous testing and approval regime, and it may take months longer to get such a vaccine to market.

Read the full article here.

Find out more about how GreenLight manufactures RNA here.

By 0 Comments

GenEdge: GreenLight Strives for Global RNA Equity

Martha Ortega-Valle, co-founder of GreenLight Biosciences, is interviewed by GenEdge to discuss how RNA equity can help solve the problems of today and the future.

Martha Ortega-Valle, co-founder of GreenLight Biosciences, is interviewed by GenEdge to discuss how RNA equity can help solve the problems of today and the future. Extracts from the interview are below:

We were coming from a solution that could manufacture in a very integrated way mRNA for agriculture. We thought those learnings were going to play an important role to accelerate the RNA space. We decided to do it, not only the manufacturing challenge but the pipeline development….

We are seeing that manufacturing and having enough vaccine doses for everyone not only in the developed world—it’s becoming an issue. Even today in Europe, countries are struggling for vaccines and doses…

We have a unified way in the sense that we think RNA can solve very important problems in the agricultural space, the human health space, and even animal health…

The beauty of that is that you’ll always have one single way of producing that molecule — one platform, a million products. That’s giving you R&D acceleration and then moving them through regulatory and commercial scale…

In ten years, I’d like to have advanced therapies using the RNA platform that can cure or alleviate diseases that don’t have good solutions. We could think about sickle cell disease, HIV, and other important diseases…

We need to make sure to integrate the local people not only in terms of getting their vaccines but also empowers them to have biomanufacturing as part of their industrial endeavors. There are wonderful universities doing great work in those locations that now have access to generate clinical materials in a facility that is local. So, it’s bringing top technologies to those locations.

Read the full article here.

Find out more about how GreenLight manufactures RNA here.

By 0 Comments

The National: Africa needs to be self-reliant in vaccine production

Andrey Zarur, CEO of GreenLight Biosciences, writes an opinion piece for The National about how vaccine production needs to progress for the world to recover from the pandemic.

Andrey Zarur, CEO of GreenLight Biosciences, writes an opinion piece for The National about how vaccine production needs to progress, particularly in Africa, for the world to recover from the pandemic. Some extracts from the piece are below.

The pandemic will not end until everyone is vaccinated – and quickly. At the current pace, full vaccination will not occur until the end of 2022, but we must find a way to make enough vaccines, about 15 billion doses, before serious vaccine-resistant variants overtake us. That’s daunting, but it is possible to meet the challenge.

Some countries may share their vaccines with others, but to produce vaccines continually and efficiently, we need production sites distributed around the world. GreenLight’s novel RNA manufacturing process – quick to start, built for scale, and using small bioreactors – may be part of the solution. We are partnering with governments, multilateral institutions and companies on all continents to accelerate pandemic response.

Vaccines for Covid-19 cannot yet be manufactured in Africa. Local manufacturing – that is to say, a factory on the continent itself – would help meet the demand and increase the pace of vaccinations. The Covax initiative plans to send 600 million doses to Africa, enough for only about 20 per cent of its population; so far only 20 million have been delivered. Africa is, essentially, at the back of the line.

The last year has been a showcase for the power of science and of human ingenuity. To go from identifying a pandemic virus to getting a vaccine for that virus into millions of arms within a year is extraordinary, when the normal process takes a decade or more. But to fight this deadly virus and all its variants requires the agility and ingenuity to equip every country with the tools it needs to stay victorious.

Read the full article here.

Find out more about how GreenLight manufactures RNA here.


By 0 Comments